Wei Research Group
Highlights of what we are doing
![[18F]RCCB6 immunoPET/CT images in a 61-year-old female patient with clear cell renal cell carcinoma](https://static.wixstatic.com/media/eceb3d_40debf81b3c5411b9287efdad122e0c8~mv2.webp/v1/fill/w_980,h_576,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/eceb3d_40debf81b3c5411b9287efdad122e0c8~mv2.webp)
[18F]RCCB6 immunoPET/CT images demonstrated multiple metastases, including lung metastases (red and green arrowheads) and a possible standalone pancreas metastasis (yellow arrowheads)
![[68Ga]Ga-NOTA-C2](https://static.wixstatic.com/media/eceb3d_3d349741e93c41c38b9431cdcdcf2cea~mv2.png/v1/fill/w_980,h_565,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/eceb3d_3d349741e93c41c38b9431cdcdcf2cea~mv2.png)
[68Ga]Ga-NOTA-C2 is a nanobody tracer targeting human CD47 with high sensitivity and specificity.
AF488-RW102 is a PD-L1 specific nanobody probe. We are exploring underlying mechanisms mediating kidney clearance and reabsorption of nanobody-derived molecular imaging tracers.
[18F]RCCB6 immunoPET/CT images demonstrated multiple metastases, including lung metastases (red and green arrowheads) and a possible standalone pancreas metastasis (yellow arrowheads)
The reason why we are running a lab at a tertiary hospital in China is pure and simple: we want to innovate molecular imaging approaches and theranostic platforms that may improve clinical management of human cancers.
Clinical nuclear Medicine
Experimental Nuclear Medicine
